For US residents only.

Understanding Side Effects

Sandostatin® LAR Depot

As with immediate-release Sandostatin® Injection, the most frequently reported adverse events with Sandostatin® LAR Depot were gallbladder disorders (52%), digestive disorders (7% to 36%), and injection-site pain (2% to 11%). Low blood sugar (2%), high blood sugar (15%), low thyroid hormone (2%), and enlargement of thyroid gland (2%) have been reported. While not measured in acromegalic patients receiving Sandostatin® LAR Depot, electrocardiogram (ECG) changes have been reported in patients receiving immediate-release Sandostatin® Injection; the degree to which these abnormalities are related to octreotide acetate is not clear, as many acromegalics have cardiovascular disease.

See the full Prescribing Information for Sandostatin® Injection and the full Prescribing Information for Sandostatin® LAR Depot.

Imagery supplied by Getty Images